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Abstract
The use of postmenopausal hormone therapy after breast cancer
remains controversial. Evidence shows variation by study design,
and even among three randomized controlled trials there is
substantial heterogeneity of results. Two Swedish trials of
comparable size show relative risks of recurrence of 3.3 and 0.82
on comparing women receiving postmenopausal hormone therapy
with control women. The extent of use of tamoxifen and
concomitant use of progestins in combination with estrogen,
although raised as one possible explanation for this heterogeneity,
are not supported by evidence from trials of high-dose progestins
used after breast cancer. Caution is needed when considering the
use of postmenopausal hormone therapy after breast cancer.
There is now resounding evidence that use of exogenous
hormones by postmenopausal women increases risk for
breast cancer [1-3]. Likewise, obesity among postmeno-
pausal women with breast cancer is a major determinant of
relapse and mortality [4,5], being directly related to poor
outcomes. On the other hand, tamoxifen provides lasting
reduction in risk for recurrence and mortality [6], an effect
that is independent of adjuvant chemotherapy. Despite this
evidence relating endogenous and exogenous hormones to
breast cancer risk and outcomes, debate continues regarding
the use of postmenopausal hormones for symptom relief
among women with breast cancer. Col and colleagues [7], in
this issue of Breast Cancer Research, report a systematic
review in which they identified eight observational studies and
two randomized controlled trials of postmenopausal hormone
therapy. They note that the combined results for the two trials
show increased risk for recurrence (relative risk [RR] = 3.4,
95% confidence interval [CI] = 1.6 to 7.3), which contrasts
with the findings of the observational results, which show a
decrease in risk (RR = 0.6, 95% CI = 0.5–0.8). While noting
heterogeneity between the results according to study design,
Col and colleagues do not explore the data to describe the
possible sources of heterogeneity [8,9] beyond study design.
As noted below, the quality of data reporting limits their ability
in this regard.
Biologic evidence supports estrogenic exposures being
related to incidence and poor outcome among women with
breast cancer. Weight after diagnosis is a strong predictor of
outcome [4], and weight gain after diagnosis is associated
with increased recurrence and mortality [5]. There are direct
positive relations between adiposity and circulating estrogens
[10], and between adult weight gain and postmenopausal
breast cancer risk [11], and circulating endogenous
hormones represent the primary explanation for this positive
relation between adiposity and postmenopausal breast
cancer incidence [12]. Together, these data support an
increase in incidence of breast cancer with use of
postmenopausal hormone therapy. Should the effect of
exogenous postmenopausal hormonal therapy differ after
diagnosis, when adiposity and weight gain have adverse
effects on recurrence and mortality?
To cloud further the current evidence, a third randomized trial
[13], which has been published since the synthesis by Col
and colleagues, found no increase in risk with use of post-
menopausal hormone therapy (RR = 0.8, 95% CI = 0.4–1.9),
based on 4.1 years of follow up in 434 women (Table 1). The
authors raise the intriguing possibility that the choice of
hormone regimen may modify the risk for recurrence and
account for some of the heterogeneity observed. This trial is
of comparable size and design to the HABITS (Hormone
Replacement Therapy after Breast Cancer – Is It Safe?) trial,
also conducted in Sweden [14]. Clearly, more detailed
analysis of this small body of evidence might improve our
understanding of the difference between unopposed
estrogen and combination estrogen plus progestin therapy
among women who have been treated for histologically
confirmed breast cancer. Alternatively, we can consider other
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evidence on use of progestins after diagnosis and breast
cancer outcomes.
Several recent studies suggested that, when drug therapies
are considered, observational studies give measures of effect
comparable to those observed through randomized trials
[15,16]. However, here we have significant heterogeneity of
results both within the randomized trials (Stockholm trial [13]
and HABITS trial [14], both conducted in Sweden) and
between the observational and randomized study findings in
the systematic review conducted by Col and coworkers [7].
As Col and colleagues note, the observational studies often
did not report results separately for women using
combination hormone therapy and those using unopposed
estrogens. It is noteworthy that the Stockholm trial attempted
to minimize the use of progestogen, and the HABITS trial
recommended either cyclical estrogen plus progestin for
women with uterine bleeding within 2 years of randomization
or continuous combined therapy for other women with a
uterus. The Stockholm trial recommended 20 mg medroxy-
progesterone acetate (MPA) for 14 days every 105 days for
women over 55 years of age. The Stockholm trial also
included a higher percentage of patients receiving conco-
mitant adjuvant tamoxifen therapy than did the HABITS trial
(52% versus 21%), and a lower percentage of patients with
node-positive breast cancer (16% versus 26%). Thus, a
lower risk population may have been studied in the
Stockholm trial, with lower exposure to MPA.
It has been hypothesized that MPA might act through
glucocorticoid receptors to reduce metastatic potential [17].
Two trials that used high-dose MPA for 6 months in women
with breast cancer and followed them for more than a decade
[18,19] fail to support a reduction in recurrence. A systematic
review of trials of MPA in combination with either tamoxifen or
combination chemotherapy after breast cancer sheds some
light on this possibility. Synthesis of data from randomized
trials published through 1996 shows no overall improvement
in median survival among women treated with MPA, and no
survival advantage for higher versus lower doses of endocrine
therapy (including MPA) [20]. Finally, given that estrogen plus
progestin clearly increases the incidence of breast cancer,
and that the Women’s Health Initiative showed that the
distribution of tumor stage was comparable in the estrogen
plus progestin arm and the placebo arm [21], treatment with
MPA before diagnosis does not appear to reduce metastatic
potential. These data combined then do not provide strong
evidence that merely the dose or frequency of MPA
administration could account for the heterogeneity among the
Swedish trials. Furthermore, these data clearly do not support
MPA as an agent to reduce recurrence and improve survival.
To conclude, given the divergent results from the randomized
trials, we recommend caution. Symptom management
remains a challenge in some postmenopausal women. The
consensus statement suggesting that other established
means of controlling symptoms or preventing osteoporosis
should be utilized before considering estrogen and progestin
therapy in these women remains prudent [22].
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